Ramoplanin oral
Alternative Names: A 16686; A 16686A; MDL 62198; NTI-851; RamoplaninLatest Information Update: 18 Jun 2021
Price :
$50 *
At a glance
- Originator Pfizer
- Developer Ology Bioservices
- Class Antiacnes; Antibacterials; Depsipeptides
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Clostridium difficile infections; Vancomycin-resistant enterococcal infections
Most Recent Events
- 01 Feb 2018 Discontinued - Phase-II for Clostridium difficile infections in USA (PO) (Ology Bioservices communication, February 2018)
- 02 Oct 2017 Nanotherapeutics is now called Ology Bioservices
- 25 Jun 2015 Phase-II development in Clostridium difficile infections is ongoing in the US